Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganoderic acid DM
- Development stage
- Preclinical
- Modality
- Classical Binding Small Molecules → Small Molecules
- Administration
- In Vitro (no Established Clinical Route; Primarily Laboratory/experimental Use)
01
Overview
Ganoderic acid DM is a triterpenoid compound isolated from the fruiting body of the medicinal mushroom *Ganoderma lucidum* (Lingzhi). It is a bioactive natural product classified as a lanostane-type triterpenoid. Ganoderic acid DM possesses **antiandrogenic, anti-osteoclastogenic, anti-cancer, and pro-apoptotic activity**. Mechanistically, it inhibits key mediators including c-Fos and NFATc1, consequently suppressing dendritic cell-specific transmembrane protein (DC-STAMP) and reducing osteoclast fusion. It also acts as an inhibitor of androgen receptor signaling and has demonstrated toxicity against both androgen-dependent and -independent prostate cancer cells, making it a potential agent for advanced prostate cancer. Recent studies highlight its **potential in breast cancer by inhibiting PIK3CA and related pathways, suggesting cell cycle arrest, apoptosis induction, and reduced cancer cell growth**. Additional inhibitory effects on 5α-reductase, PARP, CDK, NF-κB, and TNF-α have been reported, indicating broad implications for cancer therapy and immunomodulation[1][3][5][7][9].
- Other names
- ganoderate DM
02
Targets
SRD5A (Steroid 5-alpha-reductase)AR (Adrenergic receptors)CDK (CDK family)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NF-κBPARP (PARP family)PIK3CA (Phosphoinositide 3-kinase alpha)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on ganoderic acid DM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganoderic acid DM.